Moderna stock has staged one of the most dramatic comeback rallies in biotech this year, transforming a company that many investors had written off as a fading pandemic winner into one of Wall Street’s most closely watched turnaround stories. Shares have surged roughly 80% in 2026, helped by improving sentiment around Moderna’s cancer-vaccine pipeline, progress toward new product launches and growing optimism that the company can finally reduce its dependence on COVID-19 vaccine revenue. Yet after such a powerful move, investors face a much harder question than they did at the beginning of the year: has Moderna’s business improved enough to justify the enthusiasm now embedded in the stock?
That debate intensified after BofA Securities downgraded Moderna from Neutral to Underperform and cut its price target to $30 from $34, arguing that the stock’s recent appreciation had created a less attractive risk-reward profile. BofA’s analysts acknowledged progress in Moderna’s pipeline but pointed to uncertainties surrounding commercialization and the timing of meaningful revenue contributions from new products.
This does not automatically make Moderna stock a sell. It does, however, change what investors need to see next. A depressed stock can rally simply because expectations are too pessimistic; a stock that has already surged needs increasingly convincing evidence that revenue, cash flow and pipeline value are moving in the same direction.
Moderna’s Huge Rally Has Completely Changed the Investment Debate
The Moderna story entering 2026 was dominated by skepticism. COVID vaccine demand had fallen sharply from pandemic-era levels, losses remained substantial, and the company was spending heavily to develop an enormous mRNA pipeline before many of those programs were generating meaningful commercial revenue. Investors were effectively being asked to fund the transition from a one-product pandemic powerhouse into a diversified biotechnology company.
The rally changed that setup. Moderna shares have gained roughly 80% this year, and the market is increasingly assigning value to products that have not yet reached their full commercial potential. That is not necessarily irrational—biotechnology stocks routinely trade on future clinical and regulatory milestones—but it means expectations become more important with every leg higher.
Related articles
A large portion of the renewed enthusiasm revolves around Moderna’s individualized neoantigen therapy intismeran autogene, also known as mRNA-4157 or V940, which is being developed with Merck in combination with Keytruda. Moderna and Merck have been studying the treatment across several cancers, including melanoma, where earlier clinical results generated considerable investor interest.
If the program succeeds in late-stage trials and eventually reaches the market, Moderna could demonstrate that its mRNA platform is capable of producing commercially important medicines far beyond respiratory vaccines. That would fundamentally alter how investors value the company.
The problem is that Moderna still has to cross that bridge.
The Cancer Vaccine Could Be the Catalyst That Changes Everything
Few assets in Moderna’s pipeline carry as much strategic importance as its personalized cancer vaccine collaboration with Merck.
The therapy is designed to train a patient’s immune system to recognize mutations unique to that individual’s tumor. In earlier melanoma studies, combining the vaccine with Merck’s blockbuster immunotherapy Keytruda reduced the risk of recurrence or death compared with Keytruda alone, encouraging the companies to move into Phase 3 development.
For Moderna, the implications extend far beyond one potential drug. Successful commercialization would validate the central argument management has made for years: the same mRNA technology that produced a COVID vaccine at unprecedented speed could become a broader platform capable of addressing infectious diseases, oncology and rare diseases.
That platform potential is one reason MRNA stock can react dramatically to clinical data. Investors are not simply calculating the potential revenue from one cancer product. They are trying to determine whether success in one major indication raises the probability that other Moderna programs can work as well.
But biotechnology investing cuts both ways. Late-stage clinical trials remain uncertain, regulatory timelines can change, and commercial adoption cannot be assumed even after successful approval. A valuation built heavily around future products therefore becomes vulnerable when expectations move faster than the underlying clinical evidence.
That is the tension now confronting Moderna shareholders.
The Existing Business Still Has a Revenue Problem
The excitement surrounding Moderna’s pipeline can obscure an uncomfortable reality: the company’s current commercial business remains far smaller than it was during the pandemic.
Moderna reported 2025 revenue of approximately $1.9 billion, down sharply as global COVID vaccine demand continued normalizing. The company also posted a substantial annual net loss while continuing to spend heavily on research and development.
This is the central financial challenge behind the Moderna turnaround.
The company has multiple products and candidates capable of broadening its revenue base, including its RSV vaccine and next-generation respiratory products. But the transition is occurring while the COVID franchise that once generated enormous cash flows is shrinking. Moderna therefore has to manage a difficult overlap period: legacy revenue is declining faster than many new products can mature.
That gap matters enormously for investors assessing Moderna stock predictions.
A successful biotechnology company can tolerate losses while investing in valuable late-stage assets, particularly when it has sufficient cash to fund development. But persistent losses become more problematic if clinical timelines stretch, commercialization disappoints or the company needs to raise additional capital under unfavorable conditions.
The rally therefore puts increasing pressure on Moderna to show that its next generation of products can begin closing the revenue gap.
Moderna’s Cash Position Is a Major Part of the Story
One reason Moderna has been able to pursue such an ambitious pipeline is the enormous financial cushion created during the pandemic.
The company ended 2025 with roughly $8.1 billion in cash and investments, giving it considerably more flexibility than many smaller biotechnology companies attempting similarly ambitious clinical programs. Management has also been aggressively reducing costs as it tries to align spending with its post-pandemic revenue base.
That balance-sheet strength matters because drug development is expensive, unpredictable and slow. A biotech company with insufficient liquidity may eventually need to issue stock, creating dilution for existing shareholders. Moderna’s substantial cash position gives management more time to bring major programs through late-stage trials without immediately depending on capital markets.
But cash is not the same thing as profitability.
Investors need to watch Moderna’s cash burn almost as carefully as clinical data. If operating losses remain large for longer than expected, today’s impressive cash balance can decline quickly. The bull case therefore requires more than successful trials; it requires Moderna to convert its scientific pipeline into products capable of generating enough revenue to eventually support the company’s cost structure.
That is where upcoming earnings reports become particularly important.
The Next Earnings Reports Need to Show More Than Vaccine Sales
Moderna’s quarterly results have become less about whether COVID vaccine revenue beats or misses expectations by a modest amount and more about how rapidly management can reshape the economics of the company.
Investors should focus on several interconnected variables: respiratory vaccine revenue, operating expenses, research-and-development spending, cash burn, cost reductions and updated expectations for upcoming product launches. Management commentary around regulatory timelines and late-stage clinical programs may prove even more important than headline EPS.
For anyone considering how to invest in biotech stocks, Moderna provides a useful example of why conventional valuation metrics can become difficult. A price-to-earnings ratio offers limited insight when a company is losing money while investing billions in products that may not generate meaningful revenue for years.
Instead, investors have to assign probabilities to future clinical outcomes, estimate potential addressable markets and determine how much capital the company will consume before those opportunities can become profitable.
That is inherently uncertain.
And after an 80% rally, the market is assigning a higher value to those probabilities than it was only months ago.
BofA’s Downgrade Highlights the Risk After the Run-Up
BofA Securities‘ decision to move Moderna to Underperform from Neutral captures precisely how the investment equation has changed.
The argument is not necessarily that Moderna’s pipeline has deteriorated. In fact, the company’s clinical progress is a major reason shares have rallied. Instead, the issue is whether the current share price already reflects too much of that potential before the most important programs have generated commercial results.
That distinction is crucial.
A company can become fundamentally stronger while its stock simultaneously becomes less attractive on valuation. Likewise, a declining stock can become more interesting even while the underlying business remains challenged. Price determines how much optimism—or pessimism—an investor is paying for.
For Moderna, the balance has shifted dramatically.
At the beginning of the year, investors were pricing considerable skepticism into the shares. Following the rally, investors are paying considerably more for pipeline optionality, making clinical setbacks potentially more damaging to the stock.
That does not mean the rally must end. It means future gains may require stronger evidence.
The Bull Case for Moderna Stock Is Bigger Than COVID
The strongest argument supporting Moderna has little to do with another pandemic.
If the company successfully develops a portfolio spanning oncology, respiratory diseases and other therapeutic areas, investors may eventually stop viewing Moderna primarily as a COVID vaccine manufacturer. That change in perception could be enormously valuable because platform biotechnology companies can command substantially different valuations from businesses dependent on a single declining product.
The Merck cancer collaboration sits at the center of that possibility, but it is not the only program that matters. Moderna continues developing next-generation respiratory vaccines and other mRNA medicines, creating multiple opportunities for regulatory approvals and clinical readouts over the coming years.
Success across several programs would reduce dependence on any single asset and could transform the company’s revenue profile. It would also provide evidence that Moderna’s technology platform can repeatedly generate commercially viable products—arguably the most important long-term question surrounding the company.
The challenge is that investors are beginning to pay for that future before it fully exists.
What Could Break the Moderna Stock Rally?
Clinical disappointment is the most obvious risk, but it is not the only one.
Slower-than-expected regulatory approvals could push meaningful revenue further into the future. Weak RSV or respiratory vaccine sales could increase dependence on the shrinking COVID business. Higher-than-expected operating expenses could accelerate cash burn, while competition from established pharmaceutical companies could limit the commercial opportunity even for successful products.
There is also a simpler market risk: expectations.
Momentum can become self-reinforcing in biotechnology stocks when investors anticipate major clinical catalysts. But the same mechanism works in reverse when an eagerly anticipated data release produces results that are merely good rather than exceptional.
After such a large 2026 advance, Moderna may have less room for ambiguity.
The market does not necessarily need bad news to punish a stock after a major rally. Sometimes results only need to fall short of increasingly optimistic expectations.
Is Moderna Stock a Sell After Its 2026 Rally?
Reducing the Moderna debate to a simple “buy” or “sell” overlooks what has actually changed.
The bullish case has strengthened because the company is making progress toward becoming something larger than a COVID vaccine business. Its oncology partnership with Merck represents a potentially transformative opportunity, its broader mRNA pipeline offers additional shots on goal, and its multibillion-dollar cash position provides meaningful financial runway while those programs mature.
At the same time, the Moderna stock price has moved much faster than the company’s current financial results. Revenue remains dramatically below pandemic-era levels, profitability has not returned, cash continues to fund an expensive development program, and much of the long-term valuation depends on medicines that have yet to produce mature commercial revenue.
That makes the next stage of Moderna’s story very different from the first part of the rally.
Investors should watch late-stage cancer-vaccine data, respiratory vaccine sales, regulatory milestones, quarterly cash burn and management’s progress toward reducing expenses. Those factors will reveal whether the company’s fundamental improvement is beginning to catch up with the stock price.
If the cancer program delivers convincing late-stage results and Moderna successfully converts more of its pipeline into approved products, today’s rally could eventually look like the early phase of a much larger transformation. If development timelines slip or commercial launches disappoint, the market may decide that too much future success was priced in too quickly.
Moderna has already convinced investors that its post-COVID story deserves another look.
Now it has to prove that the science behind the rally can become a business big enough to justify it.
Disclaimer
This article is for informational purposes only and does not constitute financial or investment advice. Readers should conduct their own research or consult a qualified financial advisor before making investment decisions. This article was researched and drafted with the support of AI, but was reviewed, fact-checked, and edited by the editorial team before publication.
